Anixa Biosciences, Inc. (FRA:CY71)
Germany · Delayed Price · Currency is EUR 3.160
-0.940 (-22.93%)
At close: Dec 12, 2025
Anixa Biosciences Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
92.70M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Oct 31, 2024 | - | - | - |
| Oct 31, 2023 | 210.00K | - | - |
| Oct 31, 2022 | - | - | - |
| Oct 31, 2021 | 512.00K | - | - |
| Oct 31, 2020 | - | - | - |
| Oct 31, 2019 | 250.00K | -862.50K | -77.53% |
| Oct 31, 2018 | 1.11M | 750.00K | 206.90% |
| Oct 31, 2017 | 362.50K | 62.50K | 20.83% |
| Oct 31, 2016 | 300.00K | -8.96M | -96.76% |
| Oct 31, 2015 | 9.26M | 5.59M | 152.36% |
| Oct 31, 2014 | 3.67M | 3.28M | 843.12% |
| Oct 31, 2013 | 388.85K | -551.16K | -58.63% |
| Oct 31, 2012 | 940.01K | -63.18K | -6.30% |
| Oct 31, 2011 | 1.00M | 272.52K | 37.30% |
| Oct 31, 2010 | 730.68K | -325.12K | -30.79% |
| Oct 31, 2009 | 1.06M | -1.01M | -48.83% |
| Oct 31, 2008 | 2.06M | 1.58M | 323.77% |
| Oct 31, 2007 | 486.85K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Deutsche Post AG | 84.05B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
Anixa Biosciences News
- 4 weeks ago - Anixa Biosciences, Inc. (ANIX) Discusses Differentiated CAR-T Therapy and Breast Cancer Vaccine Clinical Programs Transcript - Seeking Alpha
- 4 weeks ago - Anixa Biosciences (ANIX) Unveils New Name for Ovarian Cancer Therapy - GuruFocus
- 4 weeks ago - Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization - PRNewsWire
- 5 weeks ago - Anixa Biosciences: Hard To Justify The Market's Optimism With An Upcoming Phase 1 Readout - Seeking Alpha
- 5 weeks ago - Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat - GlobeNewsWire
- 5 weeks ago - Anixa Biosciences (ANIX) Secures U.S. Patent for Breast Cancer Vaccine - GuruFocus
- 5 weeks ago - Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s - PRNewsWire
- 5 weeks ago - Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025 - PRNewsWire